Oncopeptides AB

ONCO

SE0009414576

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:46 2024-05-20 am EDT			5-day change	1st Jan Change
2.75 ^SEK	-1.08%		-14.60%	-64.10%

May. 16	Oncopeptides AB Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress	CI
Apr. 15	Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	CI

Oncopeptides AB Announces Executive Changes

August 07, 2023 at 09:07 am EDT

Oncopeptides AB (publ) announced that CEO Monica Shaw will be departing the company and transition over to Sofia Heigis who will move from the CCO role to take on the CEO role.

Latest news about Oncopeptides AB

Oncopeptides AB Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress	May. 16	CI
Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain	Apr. 15	CI
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	Apr. 04	CI
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	Mar. 27	CI
Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization	Mar. 13	MT
Transcript : Oncopeptides AB, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Oncopeptides AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Oncopeptides AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs...	Feb. 26
FDA Officially Withdraws Approval of Oncopeptides Pepaxto	Feb. 23	DJ
Oncopeptides to Assess US FDA's Withdrawal of Blood Cancer Drug Approval	Feb. 23	MT
Spanish Authority Gives Positive Recommendation for Pricing of Oncopeptides' Blood Cancer Drug	Feb. 23	MT
Oncopeptides Receives Positive Recommendation for Pepaxti by Spanish Pricing Authority	Feb. 23	CI
Oncopeptides Extends Exclusive Rights to Cancer Drug Until 2037	Feb. 15	MT
Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines	Dec. 15	CI
Oncopeptides' New CFO Takes Office	Nov. 13	MT
Oncopeptides Selects to Present Additional Data from Ocean Study	Nov. 13	CI
Oncopeptides AB Appoints Henrik Bergentoft as Chief Financial Officer	Nov. 13	CI
Transcript : Oncopeptides AB, Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Oncopeptides AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Oncopeptides AB Announces the Nomination Committee	23-10-20	CI
Oncopeptides AB Announces Its Decision to Adopt the Application Process to Allow Pertide Access to Patients with Relapsed, Refractory Multiple Myeloma	23-09-28	CI
Oncopeptides AB(OM:ONCO) dropped from S&P Global BMI Index	23-09-18	CI
Oncopeptides Secures EU Committee Backing for Expanded Indication of Multiple Myeloma Therapy; Shares Surge	23-09-14	MT
Oncopeptides AB Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results	23-09-14	CI

Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Companyâs lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Oncopeptides AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ONCOPEPTIDES AB	-64.10%	56.41M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	107B
ARGENX SE	-2.59%	21.6B
BIONTECH SE	-12.38%	22.31B
GENMAB A/S	-5.29%	19.19B
BEIGENE, LTD.	-3.35%	18.23B
WUXI APPTEC CO., LTD.	-38.57%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.26B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.37B

Bio Therapeutic Drugs

Oncopeptides AB

Equities

ONCO

SE0009414576

Biotechnology & Medical Research

Oncopeptides AB Announces Executive Changes

Latest news about Oncopeptides AB

Chart Oncopeptides AB

Company Profile

Income Statement Evolution

Ratings for Oncopeptides AB

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs